Using Monoclonal Antibody Therapies for Multiple Sclerosis: A Review

被引：7
|
作者：
Elsbernd, Paul M. [1 ]
Carter, Jonathan L. [1 ]
机构：
[1] Mayo Clin, Dept Neurol, 13400 East Shea Blvd, Scottsdale, AZ 85259 USA
来源：
BIOLOGICS-TARGETS & THERAPY | 2021年 / 15卷
关键词：
monoclonal antibodies; multiple sclerosis; relapsing; progressive; review; NATALIZUMAB ANTIBODIES; INTERFERON BETA-1A; CONTROLLED TRIAL; RISK; ALEMTUZUMAB; RITUXIMAB; OCRELIZUMAB; PLACEBO; MECHANISMS; SAFETY;
D O I：
10.2147/BTT.S267273
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Monoclonal antibody therapies have secured an important role in the therapeutic landscape for the treatment of both relapsing and progressive forms of multiple sclerosis due to their potent efficacy, convenient dosing schedules, and well-defined side effect profiles. Each therapy has unique risks and benefits associated with its specific mechanism of action which ultimately guides clinical decision-making for individual patients. This review will summarize the mechanisms of action, evidence leading to their approval, and clinically relevant considerations for each of the current monoclonal antibody therapies approved for the treatment of multiple sclerosis.
引用
收藏
页码：255 / 263
页数：9
相关论文
共 50 条
  • [31] Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies
    Singer, Barry A.
    SEMINARS IN NEUROLOGY, 2016, 36 (02) : 140 - 147
  • [32] A review of possible therapies for multiple sclerosis
    Hui Li
    Gaojian Lian
    Guang Wang
    Qianmei Yin
    Zehong Su
    Molecular and Cellular Biochemistry, 2021, 476 : 3261 - 3270
  • [33] A review of possible therapies for multiple sclerosis
    Li, Hui
    Lian, Gaojian
    Wang, Guang
    Yin, Qianmei
    Su, Zehong
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2021, 476 (09) : 3261 - 3270
  • [34] Anti-CD20 therapies for multiple sclerosis: current status and future perspectives
    Margoni, Monica
    Preziosa, Paolo
    Filippi, Massimo
    Rocca, Maria A.
    JOURNAL OF NEUROLOGY, 2022, 269 (03) : 1316 - 1334
  • [35] Monoclonal antibody therapies for the treatment of relapsing-remitting multiple sclerosis: differentiating mechanisms and clinical outcomes
    Lycke, Jan
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (06) : 274 - 293
  • [36] Monoclonal Antibody-Based Therapies for Myasthenia Gravis
    Alabbad, Sawsan
    AlGaeed, Mohanad
    Sikorski, Patricia
    Kaminski, Henry J.
    BIODRUGS, 2020, 34 (05) : 557 - 566
  • [37] Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives
    D'Amico, Emanuele
    Caserta, Cinzia
    Patti, Francesco
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2015, 15 (03) : 251 - 268
  • [38] Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates
    Dubey, Divyanshu
    Kieseier, Bernd C.
    Hartung, Hans Peter
    Hemmer, Bernhard
    Miller-Little, William A.
    Stuve, Olaf
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2015, 11 (01) : 93 - 108
  • [39] Monoclonal antibodies in treatment of multiple sclerosis
    Rommer, P. S.
    Dudesek, A.
    Stueve, O.
    Zettl, U. K.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 175 (03) : 373 - 384
  • [40] Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies
    Seliner, Johann
    Rommer, Paulus S.
    VACCINES, 2021, 9 (02) : 1 - 12
12345